

Prescribing patterns and impact of glucagon-like peptide-1 receptor agonists in a kidney transplant evaluation cohort in British Columbia, Canada

A single-center experience

Hyunwoong Harry Chae¹, Cindy Luo², David Harriman³, Christopher Nguan³

¹Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; ²Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada; ³Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

Cite as: Chae HH, Luo C, Harriman D, et al. Prescribing patterns and impact of glucagon-like peptide-1 receptor agonists in a kidney transplant evaluation cohort in British Columbia, Canada: A single-center experience. *Can Urol Assoc J* 2026;20(10):E407-14. <http://dx.doi.org/10.5489/cuaj.9689>

Published online July 7, 2026

ABSTRACT

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RA) have demonstrated weight loss and cardiometabolic benefits in specific subpopulations. Studies of GLP-1RAs in Canadian end-stage renal disease (ESRD) and kidney transplantation (KT) patients are limited.

METHODS: This is a retrospective cohort study of patients evaluated for potential KT at the Vancouver General Hospital (VGH) between January 2014 and August 2024. We analyzed prescription patterns, weight changes, and post-transplant outcomes.

RESULTS: At evaluation, 63/2789 (2.3%) patients were on a GLP-1RA. The proportion of GLP-1RA users increased from 0% in 2014–2018, to 0.3% (1/366) in 2019, and 8.7% (20/231) in 2024. There was a mean weight change of -1.82 kg (-1.93%, 95% confidence interval [CI] -3.46 to -0.19, $p=0.031$; $n=26$) at six months and -2.50 kg (-2.62%, 95% CI -4.47 to -0.52, $p=0.016$; $n=25$) at 12 months post-initiation. Twenty-six patients received a KT and had a median followup of 1.14 (interquartile range [IQR] 0.19–1.79) years. Only 11 patients were on a GLP-1RA at one year post-transplant and had available post-transplant outcome data. No significant differences were detected in estimated glomerular filtration rate (eGFR) (67, IQR 65.5–78 vs. 59, IQR 45–75 mL/min/1.73 m², $p=0.18$), graft failure (0% vs. 4.6%, $p=1$) and mortality (0% vs. 3.0%, $p=1$) between GLP-1RA users vs. non-users at one year post-KT.

CONCLUSIONS: GLP-1RA use in BC's KT evaluation cohort increased since 2019 and was associated with modest weight loss at six and 12 months post-initiation. No significant differences in post-transplant outcomes were detected. This provides preliminary support for GLP-1RAs as a potentially safe weight management strategy for Canadian KT candidates.

INTRODUCTION

Glucagon-like peptide 1 receptor agonists (GLP-1RA) are a relatively new class of medications primarily used as a glucose-lowering agent for type 2 diabetes mellitus (T2DM). They have been shown to effectively provide improved glycemic control, weight loss, and cardiovascular benefits in these patient groups.^{1–3} In recent years, multiple trials have found similar metabolic and cardiovascular benefits among non-diabetic patients.^{4,5} As such, studies have begun exploring the use of this medication in diverse patient populations, and have found improved clinical outcomes in heart failure patients, obstructive sleep apnea, non-alcoholic liver steatohepatitis, polycystic ovarian syndrome (PCOS), and anti-psychotic use-associated obesity.^{6–9}

Kidney transplant (KT)-related populations, including both potential candidates with end-stage renal disease (ESRD) or advanced chronic kidney disease (CKD G4–G5) and KT recipients, are another patient group that may benefit from the previously identified positive impacts of this medication in other clinical contexts.

First, KT is pursued for patients with ESRD who are dialysis-dependent or those with advanced CKD undergoing pre-emptive transplantation. Even after KT, recipients remain at risk for allograft injury due to persistent comorbidity and transplant-specific factors, such as immunosuppression, rejection, and

KEY MESSAGES

- GLP-IRA prescribing among a kidney transplant evaluation cohort in BC increased markedly after 2019.
- GLP-IRA use was associated with modest weight loss at six and 12 months in these potential kidney transplant candidates.
- No significant differences in one-year post-transplant outcomes were detected between GLP-IRA users and non-users.

recurrent disease. The two most common causes of CKD are hypertension and diabetes mellitus, and as such, the previously demonstrated protective effects of GLP-IRAs on metabolic and cardiovascular health suggest that these medications may be useful for KT-related populations.

Second, obesity is a significant barrier to KT accessibility, as it is considered a relative contraindication to KT in many transplant programs, contributing to delays or denial of waitlisting and transplantation.¹⁰ As such, GLP-IRA use in obese, marginal KT candidates may not only improve their metabolic and cardiovascular health, but if safe and sustainable weight loss can be achieved on this medication, it could potentially increase KT accessibility.

Despite GLP-IRAs being an actively discussed and studied medication in recent years, with increasing use in various clinical settings, there is a limited number of studies characterizing prescribing patterns of this medication in potential KT candidates (advanced CKD and ESRD) and KT recipients.^{11,12} To our knowledge, no such study exists in the Canadian context thus far.

Furthermore, while there have been large trials demonstrating improved metabolic and cardiovascular outcomes with GLP-IRA use in CKD patients,^{13,14} the evidence base for ESRD and KT patients remains limited, with most existing studies being small-scale trials or observational cohorts reporting heterogeneous findings. Some studies of ESRD and dialysis patients have identified weight loss and improved cardiometabolic parameters with GLP-IRA use, although reported effects have varied widely.¹⁵⁻¹⁹

Existing data remains similarly limited for KT recipients; while one large, retrospective registry study on KT recipients suggested improved graft outcomes and

survival rates in GLP-IRA users, it did not evaluate metabolic outcomes.²⁰ Some retrospective cohort studies have identified mild improvements in renal function, cardiovascular health, weight, graft outcomes and survival; however, many studies had limited sample sizes and reported inconsistent findings.^{11,12,21-23}

To address these gaps, the objectives of this single-center study were to characterize prescribing patterns of GLP-IRA in patients being evaluated for KT and KT recipients in BC, evaluate the association of GLP-IRA use and changes in weight, and compare post-transplant outcomes between KT recipients who were GLP-IRA users vs. non-users.

METHODS

Study design

This is a single-center, retrospective cohort study of patients evaluated for potential KT at the Vancouver General Hospital (VGH) between January 2014 and August 2024. All patients who have ESRD, are on dialysis, or have advanced CKD approaching ESRD are referred to the VGH KT clinic, where they are evaluated for eligibility for KT. Institutional records and the provincial transplant database were reviewed for data collection.

Demographic variables were collected at time of evaluation for potential KT, and included age, sex, race/ethnicity, blood group, weight and body mass index (BMI) at time of evaluation, primary etiology for CKD, and diabetes mellitus status.

Patient records were screened for patient weights and presence of GLP-IRA medication prescriptions. Trends in annual prescription prevalence of GLP-IRA medications in our cohort were analyzed by calculating the number of first-time evaluations for potential KT in which the patient was receiving a GLP-IRA at the time of evaluation, divided by the total number of evaluations performed in the same calendar year.

Weight changes at six and 12 months from prescription initiation were recorded. For each time point (i.e., time of GLP-IRA initiation, six months post-initiation, 12 months post-initiation), the weight measurement closest to the target date within a $\pm$ three-month window was used. Patients with incomplete weight data or those who discontinued their medication prior to each time point were excluded.

Post-transplant outcomes at one year, including estimated glomerular filtration rate (eGFR), graft failure, and mortality, were compared between 1) KT recipients who were receiving a GLP-IRA at the time

of initial evaluation and remained on a GLP-1RA at the one-year post-transplant timepoint; and 2) KT recipients who never received a GLP-1RA during the study period. Patients with incomplete one-year post-transplant data or those who discontinued their GLP-1RA medication prior to the one-year post-transplant timepoint were excluded.

Statistical analysis

Descriptive statistics were used to summarize demographic data. Prescription prevalence trends were presented descriptively, and annual trends were assessed via logistic regression modelling. Paired t-tests were used for weight change analyses. Post-transplant outcomes were compared via two-sample t-test or Wilcoxon rank-sum test for continuous outcomes and Chi-squared or Fisher's exact tests for categorical outcomes, with each test selected appropriately based on the data characteristics and underlying assumptions. Analyses were conducted using R 4.0.4 (R Foundation for Statistical Computing, Vienna, Austria). A p-value <0.05 was considered statistically significant.

RESULTS

Demographics

Demographic characteristics of the study cohort are summarized in Table 1. Between January 2014 and August 2024, 63/2789 (2.3%) patients evaluated for potential KT were on a GLP-1RA at the time of evaluation. Twenty-six (41.3%) subsequently received a KT within the study period, and were followed up for a median of 1.14 (interquartile range [IQR] 0.19–1.79) years post-transplant. The median age at time of initial evaluation for this cohort was 61.0 (IQR 48.5, 68.6) years, and 36/63 (57.1%) patients were male. The most common race/ethnicities reported were White (17/63, 27.0%), Southeast Asian (12/63, 19.0%), and East Asian (6/63, 9.5%), although many patients' race/ethnicity was unknown or unreported (20/63, 31.7%).

ABO blood group was most commonly O (28/63, 44.4%), A1 (16/63, 25.4%), B (13/63, 20.6%), and AB (6/63, 9.5%). The median weight and BMI at the time of evaluation were 100 (IQR 80.4, 115) kg and 34.9 (IQR 29.1, 38.7) kg/m², respectively. The most common primary etiology of CKD included diabetes (46/63, 73.0%), glomerulonephritis (5/63, 7.9%), hypertension (3/63, 4.8%), and cystic kidney disease (3/63, 4.8%). Diabetes mellitus status was assessed separately from primary CKD etiology, as patients could have diabetes without

Table 1. Demographics of GLP-1RA users at time of evaluation for potential kidney transplant

	On GLP-1RA at time of evaluation for potential KT (n=63)
Age (years)	
Median [Q1,Q3]	61.0 [48.5,68.6]
Sex	
Male	36/63 (57.1%)
Female	27/63 (42.9%)
Race/ethnicity	
White	17/63 (27.0%)
Black	1/63 (1.6%)
East Asian	6/63 (9.5%)
South Asian	4/63 (6.3%)
Southeast Asian	12/63 (19.0%)
Middle Eastern/North African	0/63 (0.0%)
Hispanic/Latino ethnicity	0/63 (0.0%)
Indigenous	3/63 (4.8%)
Unknown	20/63 (31.7%)
ABO blood group	
A1	16/63 (25.4%)
A2	0/63 (0.0%)
AB	6/63 (9.5%)
B	13/63 (20.6%)
O	28/63 (44.4%)
BMI: body mass index; GLP-1RA: glucagon-like peptide-1 receptor agonists; KT: kidney transplant.	

it being the primary cause of their kidney disease. Most patients had T2DM (55/62, 88.7%), with 3/62 (4.8%) having type 1 DM.

Prescription prevalence

Annual proportions of patients evaluated for potential KT who were on a GLP-1RA during the study period are presented in Figure 1. Between 2014 and 2018, no patient evaluated for potential KT was on any GLP-1RAs. The proportion of GLP-1RA users at the time of initial evaluation rose to 0.3% in 2019 (1/366) and 0.9% in 2020 (2/223), later increasing to 4.4% in 2021 (9/203), 4.3% in 2022 (8/184), 6.2% in 2023 (23/372), and 8.7% in 2024 (20/231). In a logistic regression

Table 1 (cont'd). Demographics of GLP-1RA users at time of evaluation for potential kidney transplant

	On GLP-1RA at time of evaluation for potential KT (n=63)
Weight (kg)	
Median [Q1,Q3]	100 [80.4,115]
Missing	2 (3.2%)
BMI	
Median [Q1,Q3]	34.9 [29.1,38.7]
Missing	2 (3.2%)
Primary etiology of chronic kidney disease	
Diabetes	46/63 (73.0%)
Glomerulonephritis	5/63 (7.9%)
Hypertension	3/63 (4.8%)
Cystic kidney disease	3/63 (4.8%)
Congenital	1/63 (1.6%)
Obstruction	2/63 (3.2%)
Drug/toxin induced	0/63 (0.0%)
Reflux	0/63 (0.0%)
Other	3/63 (4.8%)
Unknown	0/63 (0.0%)
Diabetes mellitus status	
No diabetes	4/62 (6.5%)
Type 1 diabetes	3/62 (4.8%)
Type 2 diabetes	55/62 (88.7%)
Missing	1 (1.6%)

BMI: body mass index; GLP-1RA: glucagon-like peptide-1 receptor agonists; KT: kidney transplant.

restricted to 2019–2024 (excluding years with no GLP-1RA users from 2014–2018), each additional calendar year was associated with increased GLP-1RA use (odds ratio [OR] 1.65, 95% confidence interval [CI] 1.39–2.00, $p<0.001$).

Weight change

Changes in weight of GLP-1RA users at six and 12 months post-initiation are presented in Figures 2 and 3. Mean weight change among GLP-1RA users with paired measurements was -1.82 kg (-1.93%, 95% CI -3.46 to -0.19, $p=0.031$; $n=26$) at six months post-initiation,

and -2.50 kg (-2.62%, 95% CI -4.47 to -0.52, $p=0.016$; $n=25$) at 12 months post-initiation.

Post-transplant outcomes

Estimated glomerular filtration rate at one year post-transplant was numerically higher in patients who remained on GLP-1RAs at the one-year post-transplant timepoint compared to non-users; however, the difference was not statistically significant (median 67 [IQR 65.5–78] mL/min/1.73 m² in GLP-1RA users [$n=11$] vs. 59 [45–75] for non-users [$n=1225$], $p=0.18$) (Figure 4). No graft failures (0/11, 0% vs. 60/1316, 4.6%, $p=1.00$) (Figure 5) or deaths (0/11, 0% vs. 39/1316, 3.0%, $p=1.00$) (Figure 6) occurred among GLP-1RA users at one year post-transplant; however, the difference in graft failure and mortality rates between users vs. non-users was not statistically significant.

DISCUSSION

In this single-center, retrospective cohort study of all patients evaluated for potential KT at VGH from January 2014 to August 2024, we showed that while the cumulative GLP-1RA prescription prevalence during the study period was low, at 2.3%, use has been rapidly increasing from 2019–2024, with 8.7% prevalence in 2024. GLP-1RA use was associated with modest weight loss at both six and 12 months after initiation; however, we did not detect a significant difference for one-year post-transplant outcomes, such as eGFR, graft failure, and mortality.

Although the literature is limited for ESRD patients and KT recipients, our finding of increasing use of GLP-1RAs in our KT evaluation cohort (consisting of advanced CKD and ESRD patients, as well as KT recipients) aligns with existing studies in diabetics, CKD patients, and KT recipients in other geographical contexts.

One nationwide U.S. study of KT recipients with T2DM identified that GLP-1RA use increased from 2.8% in 2014 to 12.5% in 2023.²⁴ Another multinational cohort study (Japan, Europe, and the U.S.) of CKD patients with T2DM demonstrated steadily increasing use of GLP-1RAs from 2012–2021.²⁵ In the Canadian context, a previous national study identified increasing prescription prevalence of GLP-1RAs across general populations in all provinces from 2018–2021,²⁶ and another national utilization analysis conducted by the Canadian Agency of Drugs and Technologies in Health (CADTH) identified a five-fold increase in GLP-1RA claimants from 2019–2021.²⁷

In BC, one previous study of treatment patterns for T2DM patients from 2001–2020 identified similar trends as our findings, as GLP-IRA use as first-line treatment of T2DM was less than 1% until 2015, then rising to 10% cumulative use between 2016 and 2020.²⁸ Our study adds novel insights into the utilization patterns of this medication in KT-related populations, as to the best of our knowledge, no studies specifically assessing ESRD patients or KT recipients have been conducted in BC, nor Canada thus far.

Furthermore, given that existing Canadian GLP-IRA utilization studies largely include data only through 2021, real-world prescribing patterns may have changed substantially since then in this rapidly evolving field. With early evidence suggesting not only improved glycemic control and weight loss, but also cardiovascular and renal benefits in CKD, ESRD, and KT recipients, clinical practice may be changing accordingly.^{14,20,29} As such, our study provides a timely update on GLP-IRA prescribing patterns in KT-related populations in a Canadian context.

We identified modest weight loss (-1.82 kg at six months and -2.50 kg at 12 months post-initiation) in patients evaluated for KT on GLP-IRAs. According to recently published trials, weight loss has been a proven benefit of GLP-IRAs in both T2DM patients and non-diabetic populations.^{5,30} In KT-related populations, however, existing studies are limited by small sample sizes. Reported weight loss at 12 months post-initiation in post-KT patients has been heterogeneous, ranging from no statistically significant loss to -8.8 kg.^{31–35} Reported weight loss in ESRD patients also had mixed findings, including no statistically significant weight loss at 12 weeks, -4.6 kg at 12 weeks, and -4.9 kg at a median of 17.4 months.^{15,16,19}

Compared to existing studies, the weight loss observed in our study was within the lower end of reported ranges. This variability may reflect differences across published studies in GLP-IRA agent and titration, treatment duration and adherence, baseline BMI, study design (randomized trials vs. retrospective cohorts), and followup intervals, which may limit our ability for direct comparisons with existing literature.

Our study did not identify statistically significant differences in post-transplant outcomes at one year between GLP-IRA users vs. non-users. Nonetheless, the GLP-IRA user group had numerically higher post-transplant eGFR compared to non-users and had zero mortality or graft failure events at one year post-transplant. These findings may be due to our study's limited sample size, as there were only 11 patients who were on GLP-IRAs at one year post-transplant




Figure 1. Proportion of patients evaluated for potential kidney transplantation who were on a glucagon-like peptide-1 receptor agonists (GLP-IRA) at time of evaluation. CI: confidence interval; OR: odds ratio.




Figure 2. Weight change among glucagon-like peptide-1 receptor agonists (GLP-IRA) users 6 months after initiation. CI: confidence interval.




Figure 3. Weight change among glucagon-like peptide-1 receptor agonists (GLP-IRA) users 12 months after initiation. CI: confidence interval.




Figure 4. Estimated glomerular filtration rate at one year post-transplant.




Figure 5. Graft failure at one year post-transplant.




Figure 6. Mortality at one year post-transplant.

and had available post-transplant outcome data, and our analyses were likely underpowered to detect any significant differences.

Some observational studies have recently reported lower incidences in mortality and graft failure rates, composite renal outcomes (including rejection, dialysis, re-transplantation, and mortality), and major adverse kidney events (including eGFR <15 and mortality) in GLP-1RA-using KT recipients in the U.S., Taiwan, and Israel.^{20,36,37} Despite limited power, our study provides novel preliminary Canadian data on GLP-1RA use and potential associations with post-transplant outcomes in KT-related populations, as to the best of our knowledge, no such study has been conducted thus far in the Canadian setting. These findings provide context-specific insights into the early impact of GLP-1RA medications on KT-related populations in BC and Canada more broadly, where population demographics, medication access pathways and availabilities, prescribing practices, and transplant care processes may differ from other healthcare systems and geographical contexts.

The established metabolic and cardiovascular benefits associated with GLP-1RA use in T2DM, non-diabetic, and CKD patients have driven the recent interest in exploration of GLP-1RA use among ESRD patients and KT recipients.^{3-5,14,38} If similar benefits extend to KT-related populations, GLP-1RAs could help mitigate risk of allograft injury in KT recipients, but may also provide improved transplant eligibility for obese, marginal KT candidates.

As most Canadian transplant programs have been reported to use BMI thresholds of 35–40 kg/m² for wait-list eligibility,^{39,40} and with approximately 33% of the general Canadian population being classified as obese (BMI ≥ 30 kg/m²),⁴¹ obesity is a significant barrier to transplant accessibility. Furthermore, even among KT recipients, obesity has been associated with worse post-transplant outcomes, including higher rates of delayed graft function, graft loss, and postoperative complications.^{42,43}

There are recent studies suggesting early evidence that the metabolic and cardiovascular benefits of GLP-1RAs may indeed be conferred in KT recipients and ESRD patients.^{20,31,34,36,37} Our analyses were unable to identify clear post-transplant safety signals for KT recipients on GLP-1RAs in this small sample size cohort, as we found modest weight loss at six and 12 months post-initiation and increased GLP-1RA use in our cohort in recent years; these findings may support the feasibility of GLP-1RA use as a potentially safe avenue for weight loss for obese, marginal KT candidates. Future studies with larger sample sizes, standardized exposures, and

longer followups on KT recipients and advanced CKD and ESRD patients should be conducted to clarify our understanding of the impact of these medications on KT-related populations.

Limitations

This study has limitations. First, the sample size of this cohort is limited, with 63 total patients evaluated for KT on GLP-1RA, 26 ultimately receiving KT, and only 11 having available one-year post-transplant data.

Second, heterogeneity in patients along the transplant evaluation pathway (evaluated, waitlisted, received KT) and our retrospective study design necessitated non-standardized timing of weight measurement intervals (using the closest available weight measurement to each timepoint). Additionally, there was variability in GLP-1RA agents, dosing, and treatment durations across patients. Together, these factors may have introduced measurement variability and limited comparability of weight change estimates among patients and timepoints.

Third, while the study period ended in August 2024, given the rapidly evolving literature on this topic, practice patterns and local guidelines and policies around the use of these medications may have continued to shift after our study period window. As such, the estimates of prescription prevalence reported in this study may not fully reflect current extent of use among KT-related populations.

Fourth, due to the single-center, retrospective design of this study, there is potential for selection bias, as all patients were from a single transplant program, and potential confounders such as baseline differences between GLP-1RA users and non-users (e.g., baseline metabolic health, transplant candidacy, patient motivation, engagement with care).

In the context of these limitations, these findings should be interpreted as preliminary, hypothesis-generating, observational data that may inform future, more robust studies, rather than definitive evidence regarding the safety or efficacy of these medications in the KT population.

CONCLUSIONS

Among the KT evaluation cohort at the VGH KT Program in BC, Canada, use of GLP-1RAs has increased significantly between 2019 and 2024, and use was associated with modest weight loss at six and 12 months post-initiation. Among KT recipients, we did not detect significant differences between GLP-1RA users and non-users in one-year post-transplant eGFR, graft fail-

ure, or mortality. Studies with larger patient populations must be conducted to clarify the safety profile and clinical impact of GLP-1RAs in KT-related populations.

COMPETING INTERESTS: The authors have no relevant conflicts of interest to report.

DECLARATION OF AI-ASSISTED TECHNOLOGY: During the preparation of this work, the author(s) used ChatGPT for checking grammatical and spelling errors. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.

REFERENCES

1. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. *Lancet Diabetes Endocrinol* 2017;5:251-60. doi:10.1016/S2213-8587(17)30013-X
2. Giorgino F, Benroubi M, Sun JH, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). *Diabetes Care* 2015;38:2241-9. doi:10.2337/dc14-1625
3. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2016;375:1834-44. doi:10.1056/NEJMoa1607141
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med* 2023;389:2221-32. doi:10.1056/NEJMoa2307563
5. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med* 2021;384:989-1002. doi:10.1056/NEJMoa2032183
6. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. *N Engl J Med* 2023;389:1069-84. doi:10.1056/NEJMoa2306963
7. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet* 2016;387:679-90. doi:10.1016/S0140-6736(15)00803-X
8. Elkind-Hirsch KE, Chappell N, Shaler D, et al. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: A randomized placebo-controlled-phase 3 study. *Fertil Steril* 2022;118:371-81. doi:10.1016/j.fertnstert.2022.04.027
9. Müller Alves K, Teixeira da Silva M, Kramer CK, et al. GLP-1R agonists for weight loss in psychiatric disorders: A systematic review and meta-analysis. *J Endocr Soc* 2025;9:bvaf150. doi:10.1210/endo/bvaf150
10. Wakam GK, Sheetz KH, Gerhardsinger L, et al. Population-based trends in obesity and kidney transplantation among patients with end-stage kidney disease. *Transplant Direct* 2021;7:e787. doi:10.1097/TXD.0000000000001163
11. Metoyer G, Whiteson HZ, Chen Y, et al. Utilization and outcomes of glucagon-like peptide-1 receptor agonists in posttransplant diabetes mellitus in kidney transplant recipients. *Clin Transplant* 2025;39:e70354. doi:10.1111/ctr.70354
12. Kahwaji J, Hashmi S, Parke CY, et al. Safety and efficacy of liraglutide and semaglutide in kidney transplant recipients. *Kidney360* 2025;6:848-50. doi:10.34067/KID.0000000706
13. Apperloo EM, Gorritz JL, Soler MJ, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: A randomized double-blind placebo-controlled clinical trial. *Nat Med* 2025;31:278-85. doi:10.1038/s41591-024-03327-6
14. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. *N Engl J Med* 2024;391:109-21. doi:10.1056/NEJMoa2403347
15. Long JJ, Sahi SS, Lemke AJ, et al. The use of semaglutide in patients with renal failure-A retrospective cohort study. *Endocr Pract* 2024;30:963-9. doi:10.1016/j.eprac.2024.07.008
16. Vaneck L, Kurnikowski A, Krenn S, et al. Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study. *Diabetes Obes Metab* 2024;26:5931-41. doi:10.1111/dom.15967
17. Couture J, Robert P, Beauchesne MF, et al. The real-world use of semaglutide to promote weight loss in obese adults with hemodialysis: A multicenter cross-sectional descriptive study. *Can J Kidney Health Dis* 2025;12:20543581251324588. doi:10.1177/20543581251324588

18. Krisanapan P, Suppadungsuk S, Sanpawithayakul K, et al. Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: A systematic review and meta-analysis. *Clin Kidney J* 2024;17:18. doi:10.1093/ckj/sfae018
19. Idorn T, Knop FK, Jørgensen MB, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: An investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial. *Diabetes Care* 2016;39:206-13. doi:10.2337/dc15-1025
20. Orandi BJ, Chen Y, Li Y, et al. GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: A retrospective cohort study. *Lancet Diabetes Endocrinol* 2025;13:374-83. doi:10.1016/S2213-8587(24)00371-1
21. Yugueros González A, Kanter J, Sancho A, et al. Institutional experience with new antidiabetic drugs in kidney transplant. *Transplant Proc* 2021;53:2678-80. doi:10.1016/j.transproceed.2021.08.042
22. Singh P, Pesavento TE, Washburn K, et al. Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients. *Diabetes Obes Metab* 2019;21:1061-5. doi:10.1111/dom.13619
23. Riehl-Tonn VJ, Medak KD, Rampersad C, et al. GLP-1 agonism for kidney transplant recipients: A narrative review of current evidence and future directions across the research spectrum. *Can J Kidney Health Dis* 2024;11:20543581241290316. doi:10.1177/20543581241290317
24. Hansrivijit P, Tesfaye H, Wexler DJ, et al. Utilization trends of glucose-lowering medications among adult kidney transplant recipients with type 2 diabetes in the United States. *J Clin Med* 2025;14:651. doi:10.3390/jcm14020651
25. Pladevall-Vila M, Ziemięcki R, Johannes CB, et al. Clinical profile and treatment patterns in individuals with type 2 diabetes and chronic kidney disease who initiate a GLP-1 receptor agonist: A multinational cohort study. *Diabetes Ther* 2025;16:931-54. doi:10.1007/s13300-025-01717-8
26. Riad J, Abdelmalek F, Ivers N, et al. Trends in diabetes medication prescribing from 2018 to 2021: A cross-sectional analysis. *PLoS One* 2024;19:e0307451. doi:10.1371/journal.pone.0307451
27. Vannabouathong C, Crotty C, Le K, et al. Current utilization patterns of glucagon-like peptide-1 receptor agonists: Report. Canadian Agency for Drugs and Technologies in Health; 2022. doi:10.51731/cjht.2022.434
28. Carney G, Kim JD, O'Sullivan C, et al. Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada. *BMJ Open Diabetes Res Care* 2022;10:2995. doi:10.1136/bmjdr-2022-002995
29. Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. *N Engl J Med* 2021;385:896-907. doi:10.1056/NEJMoa2108269
30. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *Lancet* 2021;397:971-84. doi:10.1016/S0140-6736(21)00213-0
31. Mahzari MM, Alluhayyan OB, Almutairi MH, et al. Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or post-transplant diabetes. *J Clin Transl Endocrinol* 2024;36:100343. doi:10.1016/j.jcte.2024.100343
32. Malik R, Ali O, Casabar M, et al. Glucagon-like peptide-1 receptor analogues in renal transplant recipients with diabetes: Medium term follow of patients from a single UK centre. *Diabet Med* 2023;40:e15057. doi:10.1111/dme.15057
33. Kim HS, Lee J, Jung CH, et al. Dulaglutide as an effective replacement for prandial insulin in kidney transplant recipients with type 2 diabetes mellitus: A retrospective review. *Diabetes Metab J* 2021;45:948-53. doi:10.4093/dmj.2020.0180
34. Vigara LA, Villanega F, Orellana C, et al. Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients. *Nefrologia (Engl Ed)* 2024;44:885-93. doi:10.1016/j.nefro.2023.06.010
35. Vigara LA, Villanega F, Orellana C, et al. Effectiveness and safety of glucagon-like peptide-1 receptor agonist in a cohort of kidney transplant recipients. *Clin Transplant* 2022;36:e14633. doi:10.1111/ctr.14633
36. Lin LC, Chen JY, Huang TTM, et al. Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients. *Cardiovasc Diabetol* 2025;24:87. doi:10.1186/s12933-025-02649-0
37. Diker Cohen T, Rudman Y, Tuijman A, et al. Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus. *Diabetes Metab* 2025;51:101624. doi:10.1016/j.diabet.2025.101624
38. Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. *N Engl J Med* 2017;377:839-48. doi:10.1056/NEJMoa1616011
39. Chan G, Soucisse M. Survey of Canadian kidney transplant specialists on the management of morbid obesity and the transplant waiting list. *Can J Kidney Health Dis* 2016;3:2054358116675344. doi:10.1177/2054358116675344
40. Hossain M, Woywodt A, Augustine T, et al. Obesity and listing for renal transplantation: Weighing the evidence for a growing problem. *Clin Kidney J* 2017;10:703-8. doi:10.1093/ckj/sfx022
41. Government of Canada, Statistics Canada. The prevalence of overweight and obesity is on the rise in Canada: New results from the Canadian Health Measures Survey, 2022 to 2024. Ottawa (ON): Statistics Canada; 2025. Available at: <https://www150.statcan.gc.ca/n1/daily-quotidien/251002/dq251002b-eng.htm> (accessed January 1, 2026)
42. Hill CJ, Courtney AE, Cardwell CR, et al. Recipient obesity and outcomes after kidney transplantation: A systematic review and meta-analysis. *Nephrol Dial Transplant* 2015;30:1403-11. doi:10.1093/ndt/gfv214
43. Lafranca JA, IJermans JNM, Betjes MGH, et al. Body mass index and outcome in renal transplant recipients: A systematic review and meta-analysis. *BMC Med* 2015;13:111. doi:10.1186/s12916-015-0340-5

CORRESPONDENCE: Dr. Christopher Ngan, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; chris.ngan@ubcurology.com